Second Sight Medical Products
11
0
1
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
27.3%
3 terminated/withdrawn out of 11 trials
66.7%
-19.8% vs industry average
0%
0 trials in Phase 3/4
50%
3 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Early Feasibility Study of the Orion Visual Cortical Prosthesis System
Role: lead
Object Finder for a Retinal Prosthesis
Role: collaborator
A Validation of the Functional Low-Vision Observer Rated Assessment (FLORA-20) for Profoundly Blind Individuals
Role: lead
Feasibility Study of a Chronic Retinal Stimulator in Retinitis Pigmentosa
Role: lead
Argus® II Retinal Stimulation System Feasibility Protocol
Role: lead
Argus II/ORCAM Device Study
Role: collaborator
New Enrollment Post-Approval Study of the Argus® II Retinal Prosthesis System
Role: lead
Post-Market Study of the Argus® II Retinal Prosthesis System - France
Role: lead
Argus® II Retinal Prosthesis System Post-Market Surveillance Study
Role: lead
Argus II Retinal Prosthesis System Dry AMD Feasibility Study Protocol
Role: lead
Argus II Retinal Prosthesis System - Better Vision RP Study
Role: lead
All 11 trials loaded